Tags

Type your tag names separated by a space and hit enter

A prospective multicenter observational study of Viperidae polyvalent immune F(ab')2 antivenom administration for the treatment of viper envenomation in dogs.
J Vet Emerg Crit Care (San Antonio). 2020 Jan; 30(1):34-40.JV

Abstract

OBJECTIVE

To test an equine-derived polyvalent viperid antivenom (EPVA) in the treatment of dogs with evidence of viper envenomation.

DESIGN

Prospective, multicenter observational study.

SETTING

Veterinary emergency and critical care hospitals.

ANIMALS

A total of 82 client-owned dogs with progressive clinical signs after viperid snakebite were enrolled in the study.

INTERVENTIONS

Equine-derived polyvalent viperid antivenom was administered at a dosage of 1 mL/kg body weight, either by IV infusion or SC injection.

MEASUREMENTS AND MAIN RESULTS

A standardized snakebite severity score (SSS) was used to characterize the severity of envenomation and the clinical course after EPVA treatment. Most dogs had improved SSS both at 4 (65.8%) and 8 hours (81.7%) following EPVA administration. Five dogs died. At the 4-week assessment, 3 dogs had slightly abnormal hematological or coagulation parameters; all other surviving dogs showed no abnormalities. Antivenom-related acute or intermediate reactions occurred in 12 dogs (14.6%).

CONCLUSIONS

In the first study on antivenom in dogs in Italy, the effects of progressive viper envenomation were stabilized or reversed in the large majority of dogs receiving EPVA, as confirmed by the SSS analyses.

Authors+Show Affiliations

Section of Veterinary Pharmacology & Toxicology, Department of Veterinary Science, University of Pisa, Pisa, Italy.Section of Veterinary Pharmacology & Toxicology, Department of Veterinary Science, University of Pisa, Pisa, Italy.Section of Veterinary Pharmacology & Toxicology, Department of Veterinary Science, University of Pisa, Pisa, Italy.Section of Veterinary Pharmacology & Toxicology, Department of Veterinary Science, University of Pisa, Pisa, Italy.Sclavo Diagnostics International, Sovicille, Italy.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study, Veterinary

Language

eng

PubMed ID

31858721

Citation

Vanni, Michele, et al. "A Prospective Multicenter Observational Study of Viperidae Polyvalent Immune F(ab')2 Antivenom Administration for the Treatment of Viper Envenomation in Dogs." Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001), vol. 30, no. 1, 2020, pp. 34-40.
Vanni M, Intorre L, Corazza M, et al. A prospective multicenter observational study of Viperidae polyvalent immune F(ab')2 antivenom administration for the treatment of viper envenomation in dogs. J Vet Emerg Crit Care (San Antonio). 2020;30(1):34-40.
Vanni, M., Intorre, L., Corazza, M., Meucci, V., & Parti, S. (2020). A prospective multicenter observational study of Viperidae polyvalent immune F(ab')2 antivenom administration for the treatment of viper envenomation in dogs. Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001), 30(1), 34-40. https://doi.org/10.1111/vec.12917
Vanni M, et al. A Prospective Multicenter Observational Study of Viperidae Polyvalent Immune F(ab')2 Antivenom Administration for the Treatment of Viper Envenomation in Dogs. J Vet Emerg Crit Care (San Antonio). 2020;30(1):34-40. PubMed PMID: 31858721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A prospective multicenter observational study of Viperidae polyvalent immune F(ab')2 antivenom administration for the treatment of viper envenomation in dogs. AU - Vanni,Michele, AU - Intorre,Luigi, AU - Corazza,Michele, AU - Meucci,Valentina, AU - Parti,Sandro, Y1 - 2019/12/19/ PY - 2017/06/23/received PY - 2018/03/19/revised PY - 2018/05/09/accepted PY - 2019/12/21/pubmed PY - 2020/4/3/medline PY - 2019/12/21/entrez KW - antivenin KW - canine KW - postexposure therapy KW - snake bite SP - 34 EP - 40 JF - Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) JO - J Vet Emerg Crit Care (San Antonio) VL - 30 IS - 1 N2 - OBJECTIVE: To test an equine-derived polyvalent viperid antivenom (EPVA) in the treatment of dogs with evidence of viper envenomation. DESIGN: Prospective, multicenter observational study. SETTING: Veterinary emergency and critical care hospitals. ANIMALS: A total of 82 client-owned dogs with progressive clinical signs after viperid snakebite were enrolled in the study. INTERVENTIONS: Equine-derived polyvalent viperid antivenom was administered at a dosage of 1 mL/kg body weight, either by IV infusion or SC injection. MEASUREMENTS AND MAIN RESULTS: A standardized snakebite severity score (SSS) was used to characterize the severity of envenomation and the clinical course after EPVA treatment. Most dogs had improved SSS both at 4 (65.8%) and 8 hours (81.7%) following EPVA administration. Five dogs died. At the 4-week assessment, 3 dogs had slightly abnormal hematological or coagulation parameters; all other surviving dogs showed no abnormalities. Antivenom-related acute or intermediate reactions occurred in 12 dogs (14.6%). CONCLUSIONS: In the first study on antivenom in dogs in Italy, the effects of progressive viper envenomation were stabilized or reversed in the large majority of dogs receiving EPVA, as confirmed by the SSS analyses. SN - 1476-4431 UR - https://www.unboundmedicine.com/medline/citation/31858721/A_prospective_multicenter_observational_study_of_Viperidae_polyvalent_immune_F_ab'_2_antivenom_administration_for_the_treatment_of_viper_envenomation_in_dogs_ L2 - https://doi.org/10.1111/vec.12917 DB - PRIME DP - Unbound Medicine ER -